Biametrics GmbH, a Tübingen, Germany-based company that develops and markets label-free analytical devices for application in life science and diagnostics, completed €3.1M in Series A funding.
Backers included LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe, which joined seed investors HTGF and Seedfonds BW.
The company intends to use the funds for the development of the operating production and sales activities as well as further advancements of its label-free analytical devices for the life science market.
Co-founded in 2010 as a spin-off at the University of Tübingen by Dr. Florian Pröll and Dr. Günther Proll, Biametrics leverages technology to offer a label-free measurement technique for the detailed characterization of native biomolecular interactions of such compounds without the need of fluorescent dyes or other markers. Its “b-screen” micro-arraying device, marketed together with the partner Berthold Technologies GmbH & Co. KG (Bad Wildbad), is capable of analyzing up to 10,000 spots per cm2 in a standard microarray format within a few minutes perfectly fitting the needs of pharmaceutical research for high-throughput screening, identification and characterization of new active compounds.
The “b-portable” is a small, mobile device for applications at the point of need. Results are obtained directly within a short time and thus the device is well suited for the use in process control, e.g. in bioreactors and fermenters, or in human and veterinary diagnostics.